VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SANA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SANASana Biotechnology, Inc.
$1.85$515M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSANAFinancials

Sana Biotechnology, Inc. (SANA) Income Statement

8Y historyFree accessUpdated daily

Sana reported no meaningful revenue across most quarters, with operating losses reaching $95.0 million in 2025Q2 and R&D expense ranging from $24.0 million to $54.6 million per quarter, so cost trajectory rather than sales momentum drives results.

Income StatementBalance SheetCash FlowRatios

SANA Income Statement

Annual statement

SANA Income Statement

Sana Biotechnology, Inc. (SANA) annual income statement — 8-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Sales/Revenue000000000
Revenue Growth %---------
Cost of Goods Sold2.39M12.75M000010.17M3.92M1K
COGS % of Revenue---------
Gross Profit-2.39M-12.75M0000-10.17M-3.92M-1K
Gross Margin %---------
Gross Profit Growth %-----100%-159.4%--
Operating Expenses143.59M178.21M272.72M293.14M272.56M356.91M150.95M141.15M8.22M
OpEx % of Revenue---------
Selling, General & Admin45.37M44.3M64.04M73.3M71.56M50.41M28.27M21.78M4.21M
SG&A % of Revenue---------
Research & Development161.6M131.98M208.68M219.84M201M306.5M122.68M119.38M4.01M
R&D % of Revenue---------
Other Operating Expenses-1000K1.93M0000000
Operating Income-145.98M-190.96M-272.72M-293.14M-272.56M-356.91M-161.12M-141.15M-8.22M
Operating Margin %---------
Operating Income Growth %-29.98%6.97%-7.55%23.63%-121.51%-14.15%-1616.97%-
EBITDA-130.27M-178.21M-257.22M-268.58M-256.94M-345.84M-155.2M-139.33M-8.22M
EBITDA Margin %---------
EBITDA Growth %42%30.72%4.23%-4.53%25.71%-122.83%-11.39%-1594.96%-
D&A (Non-Cash Add-back)15.71M12.75M15.5M24.56M15.63M11.07M5.92M1.83M1K
EBIT-149.27M-244.17M-266.76M-283.25M-269.48M-355.93M-297.2M-142.82M-13.25M
Net Interest Income1.73M3.85M10.47M9.94M3.76M676K747K2.86M0
Interest Income1.73M3.85M10.47M9.94M3.76M676K747K2.86M0
Interest Expense000000000
Other Income/Expense-3.29M-53.21M5.96M9.89M3.09M981K-136.08M2.83M-5.03M
Pretax Income-149.27M-244.17M-266.76M-283.25M-269.48M-355.93M-297.2M-138.32M-13.25M
Pretax Margin %---------
Income Tax000000-11.9M-7.55M0
Effective Tax Rate %0%0%0%0%0%0%4%5.46%0%
Net Income-149.27M-244.17M-266.76M-283.25M-269.48M-355.93M-285.31M-130.78M-13.25M
Net Margin %---------
Net Income Growth %36.32%8.47%5.82%-5.11%24.29%-24.75%-118.16%-887.23%-
Net Income (Continuing)-149.27M-244.17M-266.76M-283.25M-269.48M-355.93M-285.31M-130.78M-13.25M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)-0.48-0.96-1.16-1.46-1.43-2.14-1.63-0.70-0.07
EPS Growth %46.39%17.24%20.55%-2.1%33.18%-31.29%-132.86%-890.1%-
EPS (Basic)--0.96-1.16-1.46-1.43-2.14-1.63-0.70-0.07
Diluted Shares Outstanding308.79M253.23M230.89M194.54M188.34M166.43M187.51M187.34M187.34M
Basic Shares Outstanding307M253.23M230.89M194.54M188.34M166.43M187.51M187.34M187.34M
Dividend Payout Ratio---------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Liquidity runway constraint

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Pre-Revenue Status Limits Growth Assessment

Based on reported figures, Sana generated no meaningful revenue across most recent quarters, with only a $2.4 million COGS line appearing in 2026Q1, leaving revenue growth analysis largely unavailable and the trajectory driven by expense timing rather than sales momentum.

The income statement shows revenue as blank for every reported quarter, so the standard growth trend cannot be assessed and no conclusion about revenue durability should be drawn from the data. The 2026Q1 COGS entry without matching revenue suggests cost recognition ahead of any sales base, which warrants investigation of the underlying accounting treatment. Investors should treat trajectory here as a function of R&D spending cadence rather than commercial traction.

Operating Losses Driven by R&D Intensity

As reported in financial statements, Sana's R&D expense ranged from $24.0 million to $54.6 million per quarter, with operating losses of up to $95.0 million in 2025Q2, indicating that the cost base is set by clinical program scale rather than revenue.

Because operating income tracks R&D nearly one-for-one, there is no evidence of operating leverage in the conventional sense, as the business has no gross profit base to scale against. SG&A remained comparatively stable between $10.3 million and $17.3 million per quarter, suggesting overhead has not expanded in step with R&D. Investors should monitor whether R&D spending moderates as programs advance, since that is the primary lever on the loss trajectory.

Positive Quarter Reflects Non-Operating Swing

Based on Sana's reported figures, the 2026Q3 net income of $20.4 million turned positive despite an operating income of $18.5 million, a result that may reflect non-operating items warranting closer examination.

The 2026Q3 EPS of $0.07 arrives after several quarters of losses averaging roughly $0.20 per share, and the single positive quarter should not be extrapolated into a profitability trend. Stock-based compensation of $5.3 million to $11.4 million per quarter is a material non-cash charge that depresses reported losses differently from cash burn. The reconciliation between operating and net income in 2026Q3 appears to be the key item to verify in the filing.

R&D Dominates a Non-Discretionary Cost Base

According to recent SEC filings, Sana's R&D expense of $33.9 million in 2026Q3 against SG&A of $10.9 million shows that roughly three-quarters of operating spend is directed at clinical development rather than overhead.

The cost structure is concentrated in R&D, which is largely non-discretionary if the company intends to advance SC291, SC451 and related programs through the clinical pipeline. SG&A has remained within a narrow band, which suggests disciplined overhead management relative to program spending. Investors should view continued R&D intensity as consistent with the stated development strategy while recognizing it sets a high baseline burn rate.

Cash Runway Risk Overshadows Loss Narrowing

Based on reported figures, Sana's $71.87 million cash position against quarterly operating losses frequently exceeding $40 million suggests a limited runway that could force dilutive financing before clinical milestones are reached.

The single profitable quarter in 2026Q3 does not offset a pattern of recurring operating losses, and a short-seller would likely argue that the positive EPS is a non-recurring artifact rather than an inflection. With a Debt-to-Equity ratio of 0.49 and reported ROE of -118.7%, the balance sheet offers limited cushion against further losses. This suggests a meaningful probability of equity issuance at unfavorable valuations, which warrants further investigation as the next filings are reviewed.

SANA — Frequently Asked Questions

Quick answers to the most common questions about buying SANA stock.

What was Sana Biotechnology, Inc.'s (SANA) revenue in 2025?

For fiscal year 2025, Sana Biotechnology, Inc. (SANA) reported total revenue of $0.0M.

Is Sana Biotechnology, Inc. (SANA) profitable?

Sana Biotechnology, Inc. (SANA) reported a net loss of $244.2M for the fiscal year ending 2025.